Kemwell and Boehringer set to finish biologics plant in India

By Natalie Morrison

- Last updated on GMT

Related tags Manufacturing

Kemwell is set to complete a new biologics manufacturing facility in Bangalore, India, following its long-term partnership with Boehringer Ingelheim.

The firms teamed up to build the plant – a mini version of Boehringer’s German bio facility – three years ago​, with plans for a mutually beneficial partnership afterwards.

Speaking to in-PharmaTechnologist and Outsourcing-Pharma at this year’s Interphex in New York, Kemwell’s director of corporate development Christian Ahlmark said the firm would support clinical and small scale commercial production through the plant, whilst Boehringer would take large-scale clients.

The plant – which will produce monoclonal and peptides for small scale projects, amongst other things – will be completed in Q3 this year.

Ahlmark also spoke to us about Kemwell’s recently opened cGMP (current good manufacturing practice) oral liquid dose plant in India.

“That is serving a global market, where previously our Indian operations were solely for India, and it’s capable of 300m bottles of oral liquid product per year,”​ he said.

Related news

Show more

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

Related suppliers

Follow us


View more